1
|
Kondo Y, Achouri NL, Falou HA, Atar L, Aumann T, Baba H, Boretzky K, Caesar C, Calvet D, Chae H, Chiga N, Corsi A, Delaunay F, Delbart A, Deshayes Q, Dombrádi Z, Douma CA, Ekström A, Elekes Z, Forssén C, Gašparić I, Gheller JM, Gibelin J, Gillibert A, Hagen G, Harakeh MN, Hirayama A, Hoffman CR, Holl M, Horvat A, Horváth Á, Hwang JW, Isobe T, Jiang WG, Kahlbow J, Kalantar-Nayestanaki N, Kawase S, Kim S, Kisamori K, Kobayashi T, Körper D, Koyama S, Kuti I, Lapoux V, Lindberg S, Marqués FM, Masuoka S, Mayer J, Miki K, Murakami T, Najafi M, Nakamura T, Nakano K, Nakatsuka N, Nilsson T, Obertelli A, Ogata K, de Oliveira Santos F, Orr NA, Otsu H, Otsuka T, Ozaki T, Panin V, Papenbrock T, Paschalis S, Revel A, Rossi D, Saito AT, Saito TY, Sasano M, Sato H, Satou Y, Scheit H, Schindler F, Schrock P, Shikata M, Shimizu N, Shimizu Y, Simon H, Sohler D, Sorlin O, Stuhl L, Sun ZH, Takeuchi S, Tanaka M, Thoennessen M, Törnqvist H, Togano Y, Tomai T, Tscheuschner J, Tsubota J, Tsunoda N, Uesaka T, Utsuno Y, Vernon I, Wang H, Yang Z, Yasuda M, Yoneda K, Yoshida S. Publisher Correction: First observation of 28O. Nature 2023; 623:E13. [PMID: 37935927 PMCID: PMC10665181 DOI: 10.1038/s41586-023-06815-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2023]
Affiliation(s)
- Y Kondo
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan.
- RIKEN Nishina Center, Saitama, Japan.
| | - N L Achouri
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - H Al Falou
- Lebanese University, Beirut, Lebanon
- Lebanese-French University of Technology and Applied Sciences, Deddeh, Lebanon
| | - L Atar
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz Research Academy Hesse for FAIR, Darmstadt, Germany
| | - H Baba
- RIKEN Nishina Center, Saitama, Japan
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - D Calvet
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - H Chae
- Institute for Basic Science, Daejeon, Republic of Korea
| | - N Chiga
- RIKEN Nishina Center, Saitama, Japan
| | - A Corsi
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - F Delaunay
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - A Delbart
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - Q Deshayes
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | | | - C A Douma
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - A Ekström
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | | | - C Forssén
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - I Gašparić
- RIKEN Nishina Center, Saitama, Japan
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- Ruđer Bošković Institute, Zagreb, Croatia
| | - J-M Gheller
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - J Gibelin
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - A Gillibert
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - G Hagen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - M N Harakeh
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - A Hirayama
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - C R Hoffman
- Physics Division, Argonne National Laboratory, Argonne, IL, USA
| | - M Holl
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - A Horvat
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - Á Horváth
- Eötvös Loránd University, Budapest, Hungary
| | - J W Hwang
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | - T Isobe
- RIKEN Nishina Center, Saitama, Japan
| | - W G Jiang
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - J Kahlbow
- RIKEN Nishina Center, Saitama, Japan
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | | | - S Kawase
- Department of Advanced Energy Engineering Science, Kyushu University, Fukuoka, Japan
| | - S Kim
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | | | - T Kobayashi
- Department of Physics, Tohoku University, Miyagi, Japan
| | - D Körper
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - S Koyama
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - I Kuti
- Atomki, Debrecen, Hungary
| | - V Lapoux
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - S Lindberg
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - F M Marqués
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - S Masuoka
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - J Mayer
- Institut für Kernphysik, Universität zu Köln, Köln, Germany
| | - K Miki
- Department of Physics, Tohoku University, Miyagi, Japan
| | - T Murakami
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Najafi
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- RIKEN Nishina Center, Saitama, Japan
| | - K Nakano
- Department of Advanced Energy Engineering Science, Kyushu University, Fukuoka, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Nilsson
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - A Obertelli
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - K Ogata
- Department of Physics, Kyushu University, Fukuoka, Japan
- Research Center for Nuclear Physics, Osaka University, Osaka, Japan
- Department of Physics, Osaka City University, Osaka, Japan
| | - F de Oliveira Santos
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - N A Orr
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - H Otsu
- RIKEN Nishina Center, Saitama, Japan
| | - T Otsuka
- RIKEN Nishina Center, Saitama, Japan
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - V Panin
- RIKEN Nishina Center, Saitama, Japan
| | - T Papenbrock
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - A Revel
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - D Rossi
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - T Y Saito
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - M Sasano
- RIKEN Nishina Center, Saitama, Japan
| | - H Sato
- RIKEN Nishina Center, Saitama, Japan
| | - Y Satou
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - F Schindler
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - P Schrock
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - N Shimizu
- Center for Computational Sciences, University of Tsukuba, Ibaraki, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Saitama, Japan
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | - O Sorlin
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - L Stuhl
- RIKEN Nishina Center, Saitama, Japan
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
| | - Z H Sun
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - S Takeuchi
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - M Tanaka
- Department of Physics, Osaka University, Osaka, Japan
| | - M Thoennessen
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, MI, USA
| | - H Törnqvist
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- Department of Physics, Rikkyo University, Tokyo, Japan
| | - T Tomai
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - J Tscheuschner
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - N Tsunoda
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - T Uesaka
- RIKEN Nishina Center, Saitama, Japan
| | - Y Utsuno
- Advanced Science Research Center, Japan Atomic Energy Agency, Ibaraki, Japan
| | - I Vernon
- Department of Mathematical Sciences, Durham University, Durham, UK
| | - H Wang
- RIKEN Nishina Center, Saitama, Japan
| | - Z Yang
- RIKEN Nishina Center, Saitama, Japan
| | - M Yasuda
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - K Yoneda
- RIKEN Nishina Center, Saitama, Japan
| | - S Yoshida
- Liberal and General Education Center, Institute for Promotion of Higher Academic Education, Utsunomiya University, Tochigi, Japan
| |
Collapse
|
2
|
Kondo Y, Achouri NL, Falou HA, Atar L, Aumann T, Baba H, Boretzky K, Caesar C, Calvet D, Chae H, Chiga N, Corsi A, Delaunay F, Delbart A, Deshayes Q, Dombrádi Z, Douma CA, Ekström A, Elekes Z, Forssén C, Gašparić I, Gheller JM, Gibelin J, Gillibert A, Hagen G, Harakeh MN, Hirayama A, Hoffman CR, Holl M, Horvat A, Horváth Á, Hwang JW, Isobe T, Jiang WG, Kahlbow J, Kalantar-Nayestanaki N, Kawase S, Kim S, Kisamori K, Kobayashi T, Körper D, Koyama S, Kuti I, Lapoux V, Lindberg S, Marqués FM, Masuoka S, Mayer J, Miki K, Murakami T, Najafi M, Nakamura T, Nakano K, Nakatsuka N, Nilsson T, Obertelli A, Ogata K, de Oliveira Santos F, Orr NA, Otsu H, Otsuka T, Ozaki T, Panin V, Papenbrock T, Paschalis S, Revel A, Rossi D, Saito AT, Saito TY, Sasano M, Sato H, Satou Y, Scheit H, Schindler F, Schrock P, Shikata M, Shimizu N, Shimizu Y, Simon H, Sohler D, Sorlin O, Stuhl L, Sun ZH, Takeuchi S, Tanaka M, Thoennessen M, Törnqvist H, Togano Y, Tomai T, Tscheuschner J, Tsubota J, Tsunoda N, Uesaka T, Utsuno Y, Vernon I, Wang H, Yang Z, Yasuda M, Yoneda K, Yoshida S. First observation of 28O. Nature 2023; 620:965-970. [PMID: 37648757 PMCID: PMC10630140 DOI: 10.1038/s41586-023-06352-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 06/21/2023] [Indexed: 09/01/2023]
Abstract
Subjecting a physical system to extreme conditions is one of the means often used to obtain a better understanding and deeper insight into its organization and structure. In the case of the atomic nucleus, one such approach is to investigate isotopes that have very different neutron-to-proton (N/Z) ratios than in stable nuclei. Light, neutron-rich isotopes exhibit the most asymmetric N/Z ratios and those lying beyond the limits of binding, which undergo spontaneous neutron emission and exist only as very short-lived resonances (about 10-21 s), provide the most stringent tests of modern nuclear-structure theories. Here we report on the first observation of 28O and 27O through their decay into 24O and four and three neutrons, respectively. The 28O nucleus is of particular interest as, with the Z = 8 and N = 20 magic numbers1,2, it is expected in the standard shell-model picture of nuclear structure to be one of a relatively small number of so-called 'doubly magic' nuclei. Both 27O and 28O were found to exist as narrow, low-lying resonances and their decay energies are compared here to the results of sophisticated theoretical modelling, including a large-scale shell-model calculation and a newly developed statistical approach. In both cases, the underlying nuclear interactions were derived from effective field theories of quantum chromodynamics. Finally, it is shown that the cross-section for the production of 28O from a 29F beam is consistent with it not exhibiting a closed N = 20 shell structure.
Collapse
Affiliation(s)
- Y Kondo
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan.
- RIKEN Nishina Center, Saitama, Japan.
| | - N L Achouri
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - H Al Falou
- Lebanese University, Beirut, Lebanon
- Lebanese-French University of Technology and Applied Sciences, Deddeh, Lebanon
| | - L Atar
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz Research Academy Hesse for FAIR, Darmstadt, Germany
| | - H Baba
- RIKEN Nishina Center, Saitama, Japan
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - D Calvet
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - H Chae
- Institute for Basic Science, Daejeon, Republic of Korea
| | - N Chiga
- RIKEN Nishina Center, Saitama, Japan
| | - A Corsi
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - F Delaunay
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - A Delbart
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - Q Deshayes
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | | | - C A Douma
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - A Ekström
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | | | - C Forssén
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - I Gašparić
- RIKEN Nishina Center, Saitama, Japan
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- Ruđer Bošković Institute, Zagreb, Croatia
| | - J-M Gheller
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - J Gibelin
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - A Gillibert
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - G Hagen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - M N Harakeh
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - A Hirayama
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - C R Hoffman
- Physics Division, Argonne National Laboratory, Argonne, IL, USA
| | - M Holl
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - A Horvat
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - Á Horváth
- Eötvös Loránd University, Budapest, Hungary
| | - J W Hwang
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | - T Isobe
- RIKEN Nishina Center, Saitama, Japan
| | - W G Jiang
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - J Kahlbow
- RIKEN Nishina Center, Saitama, Japan
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | | | - S Kawase
- Department of Advanced Energy Engineering Science, Kyushu University, Fukuoka, Japan
| | - S Kim
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | | | - T Kobayashi
- Department of Physics, Tohoku University, Miyagi, Japan
| | - D Körper
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - S Koyama
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - I Kuti
- Atomki, Debrecen, Hungary
| | - V Lapoux
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - S Lindberg
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - F M Marqués
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - S Masuoka
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - J Mayer
- Institut für Kernphysik, Universität zu Köln, Köln, Germany
| | - K Miki
- Department of Physics, Tohoku University, Miyagi, Japan
| | - T Murakami
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M Najafi
- ESRIG, University of Groningen, Groningen, The Netherlands
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- RIKEN Nishina Center, Saitama, Japan
| | - K Nakano
- Department of Advanced Energy Engineering Science, Kyushu University, Fukuoka, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T Nilsson
- Institutionen för Fysik, Chalmers Tekniska Högskola, Göteborg, Sweden
| | - A Obertelli
- Irfu, CEA, Université Paris-Saclay, Gif-sur-Yvette, France
| | - K Ogata
- Department of Physics, Kyushu University, Fukuoka, Japan
- Research Center for Nuclear Physics, Osaka University, Osaka, Japan
- Department of Physics, Osaka City University, Osaka, Japan
| | - F de Oliveira Santos
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - N A Orr
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
| | - H Otsu
- RIKEN Nishina Center, Saitama, Japan
| | - T Otsuka
- RIKEN Nishina Center, Saitama, Japan
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - V Panin
- RIKEN Nishina Center, Saitama, Japan
| | - T Papenbrock
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - A Revel
- LPC Caen UMR6534, Université de Caen Normandie, ENSICAEN, CNRS/IN2P3, Caen, France
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - D Rossi
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - T Y Saito
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - M Sasano
- RIKEN Nishina Center, Saitama, Japan
| | - H Sato
- RIKEN Nishina Center, Saitama, Japan
| | - Y Satou
- Department of Physics and Astronomy, Seoul National University, Seoul, Republic of Korea
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - F Schindler
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - P Schrock
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - N Shimizu
- Center for Computational Sciences, University of Tsukuba, Ibaraki, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Saitama, Japan
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | - O Sorlin
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Caen, France
| | - L Stuhl
- RIKEN Nishina Center, Saitama, Japan
- Center for Exotic Nuclear Studies, Institute for Basic Science, Daejeon, Republic of Korea
| | - Z H Sun
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, USA
| | - S Takeuchi
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - M Tanaka
- Department of Physics, Osaka University, Osaka, Japan
| | - M Thoennessen
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, MI, USA
| | - H Törnqvist
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- Department of Physics, Rikkyo University, Tokyo, Japan
| | - T Tomai
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - J Tscheuschner
- Institut für Kernphysik, Technische Universität Darmstadt, Darmstadt, Germany
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - N Tsunoda
- Center for Nuclear Study, The University of Tokyo, Saitama, Japan
| | - T Uesaka
- RIKEN Nishina Center, Saitama, Japan
| | - Y Utsuno
- Advanced Science Research Center, Japan Atomic Energy Agency, Ibaraki, Japan
| | - I Vernon
- Department of Mathematical Sciences, Durham University, Durham, UK
| | - H Wang
- RIKEN Nishina Center, Saitama, Japan
| | - Z Yang
- RIKEN Nishina Center, Saitama, Japan
| | - M Yasuda
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - K Yoneda
- RIKEN Nishina Center, Saitama, Japan
| | - S Yoshida
- Liberal and General Education Center, Institute for Promotion of Higher Academic Education, Utsunomiya University, Tochigi, Japan
| |
Collapse
|
3
|
Holtdirk F, Zindler T, Mehnert A, Bültmann O, Weiss M, Mayer J, Meyer B, Specht A, Bröde P, Claus M, Watzl C, Cheng F. Digital health applications to support patients with breast cancer: Effects of two tailored, dialogue-based programs on quality of life. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01501-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Deibert W, Ivanova M, Ran K, Mayer J, Meulenberg W. Up-scaling and processing related characterisation of hydrogen permeation membranes based on pristine and Mo substituted La28−xW4+xO54+1.5x. Ann Ital Chir 2022. [DOI: 10.1016/j.jeurceramsoc.2022.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Garcia-Manero G, Bart S, McCloskey JK, Fenaux P, Selleslag D, Reda G, Valcárcel D, Santini V, Mayer J, Xicoy B, Yamaguchi H, Lübbert M, Miyazaki Y, Keer H, Hao Y, Azab M, Döhner H. P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845956.26644.d0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
6
|
Zhang Z, Albadawi H, Altun I, Mayer J, Oklu R. Abstract No. 501 Treatment of ruptured and non-ruptured aneurysms using catheter-delivered biomaterials. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Franke I, Streb J, Dudeck M, Mayer J, Steiner I, Wolf V. Alcohol use disorder as a risk factor for violent offending in a sample of female forensic-psychiatric inpatients. Eur Psychiatry 2022. [PMCID: PMC9564744 DOI: 10.1192/j.eurpsy.2022.883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Female gender is associated with a lower risk for aggressive behaviour and violent offending. Well established risk factors for aggressive behaviour are alcohol and other substance use, but previous studies focused mainly on male offenders and the general population. However, for therapeutic and prognostic reasons it is important to understand pathways to female offending. Objectives To examine a sample of female forensic-psychiatric inpatients regarding the association of alcohol (AUD) and other substance use disorders (SUD) with violent offending (homicide, assault, robbery). Methods We conducted a retrospective cohort study of 334 female patients discharged before 01.01.2019 from a secure psychiatric hospital in Germany. Results In total, 72% of the patients with AUD committed a violent crime, leading to admission to secure psychiatric treatment. In comparison a statistically significant lower rate (19%) of the SUD group was convicted of violent offending. Over 70% of the participants with AUD had a family history of AUD, and over 83% experienced physical violence in adulthood. We found no group differences (AUD vs. SUD) regarding aggressive behaviour during inpatient treatment. Conclusions According to our results, AUD compared to other SUD, is a significant risk factor for violent offending in women. A family background with AUD and a history of physical abuse might function as a risk factor for both: developing an AUD and violent offending. The comparable rates of aggression in both groups during inpatient treatment suggest that abstinence is a protective factor. Disclosure No significant relationships.
Collapse
|
8
|
Strecker A, Salzberger U, Mayer J. Probenpräparation für die Transmissionselektronenmikroskopie: Verläßliche Methode für Querschnitte und brüchige Materialien/ Specimen Preparation for Transmission Electron Microscopy: Reliable Method for Cross-Sections and Brittle Materials. ACTA ACUST UNITED AC 2021. [DOI: 10.1515/pm-1993-301002] [Citation(s) in RCA: 124] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Starzer A, Kreminger J, Berger J, Moik F, Rauchwarter M, Mayer J, Haselboeck H, Heller G, Preusser M, Berghoff A. 1877P Fatigue changes according to systemic therapy type in patients with advanced solid cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Sandecka V, Adam Z, Krejci M, Stork M, Rehak Z, Koukalova R, Sevcikova S, Brozova L, Kral Z, Mayer J, Pour L. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience. Neoplasma 2020; 67:939-945. [PMID: 32567936 DOI: 10.4149/neo_2020_191104n1137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 02/06/2020] [Indexed: 12/22/2022]
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenström macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.
Collapse
Affiliation(s)
- V Sandecka
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - Z Adam
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - M Krejci
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - M Stork
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - Z Rehak
- Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - R Koukalova
- Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - S Sevcikova
- Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - L Brozova
- Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - Z Kral
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| | - L Pour
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic
| |
Collapse
|
11
|
Stahl JH, Kegele J, Winter N, Lindig T, Schuhmann M, Godel T, Bendszus M, Kolbenschlag J, Grimm A, Daigeler A, Mayer JA. „Spontane Läsion des N. interosseus anterior
– eine interdisziplinäre
Herausforderung“. KLIN NEUROPHYSIOL 2020. [DOI: 10.1055/a-1100-2196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- J H Stahl
- Zentrum für Neurologie, Universitätsklinikum
Tübingen
| | - J Kegele
- Zentrum für Neurologie, Universitätsklinikum
Tübingen
| | - N Winter
- Zentrum für Neurologie, Universitätsklinikum
Tübingen
| | - T Lindig
- Neuroradiologie, Universitätsklinikum
Tübingen
| | - M Schuhmann
- Neurochirurgie, Universitätsklinikum Tübingen
| | - T Godel
- Abteilung für Neuroradiologie, Universitätsklinikum
Heidelberg
| | - M Bendszus
- Abteilung für Neuroradiologie, Universitätsklinikum
Heidelberg
| | - J Kolbenschlag
- Klinik für Hand-, Plastische, Rekonstruktive und
Verbrennungschirurgie, BG Klinik Tübingen
| | - A Grimm
- Zentrum für Neurologie, Universitätsklinikum
Tübingen
| | - A Daigeler
- Klinik für Hand-, Plastische, Rekonstruktive und
Verbrennungschirurgie, BG Klinik Tübingen
| | - J A Mayer
- Klinik für Hand-, Plastische, Rekonstruktive und
Verbrennungschirurgie, BG Klinik Tübingen
| |
Collapse
|
12
|
Kirstein B, Neudeck S, Kronborg MB, El-Armouche A, Gaspar T, Piorkowski J, Wechselberger S, Zedda A, Tomala J, Mayer J, Wagner M, Ulbrich S, Richter U, Huo Y, Piorkowski C. P457Incidence of LA fibrosis and substrate-based AF ablation success rates in HF patients. Europace 2020. [DOI: 10.1093/europace/euaa162.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
The author(s) received no specific funding for this work.
Background
In heart failure (HF) patients, sinus rhythm maintenance after catheter ablation for atrial fibrillation (AF) is mandatory to achieve better long-term outcome. Presence of left atrial (LA) fibrosis significantly attenuates ablation success rates. Incidence of LA fibrosis and the effect of an individualized substrate-based ablation concept on rhythm outcome in HF patients with AF is unclear.
Methods
This study investigated 103 patients (64 years, 69% men) with persistent AF (79%) and left ventricular (LV) dysfunction (EF 33% IQR [25; 38]) undergoing first time AF ablation. Identification of LA fibrosis and selection of ablation strategy were based on sinus rhythm voltage mapping. All patients received pulmonary vein isolation (PVI). LA fibrosis ablation was individualized by (i) homogenization of small areas, (ii) linear lesions connecting fibrosis and anatomical obstacles and (iii) linear lesions isolating large fibrotic areas. Rhythm outcome was measured by continuous device monitoring (AF detection ≥ 6 min) or Holter-ECG. A total post-procedural AF burden < 0.1% was defined as successful rhythm control.
Results
LA fibrosis in the overall cohort, in paroxysmal and persistent AF patients was detected in 39/103 (38%), 6/22 (27%) and 33/81 (41%), respectively. After 11 ± 5 months and 1.2 procedures/patient, freedom from AF recurrence was similar between patients with and without LA fibrosis (33/39 (84%) vs. 54/64 (84%); p = 0.485). With continuous monitoring, 73/87 (84%) patients recorded a total AF burden < 0.1%. There was no significant difference in AF burden outcome between patients with and without LA fibrosis (3.1% SD ±17.4 vs. 2.2% SD ±8.1; p = 0.4). No correlation between presence or extent of LA fibrosis and AF burden was found; p = 0.299.
Conclusion
A substantial number of HF patients with AF have no evidence of LA fibrosis. Among HF patients with LA fibrosis, individualized substrate-based AF ablation beyond PVI was able to achieve similar ablation success.
Collapse
Affiliation(s)
- B Kirstein
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Neudeck
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - M B Kronborg
- Aarhus University Hospital, Cardiology, Aarhus, Denmark
| | - A El-Armouche
- University Hospital Dresden, Pharmacology, Dresden, Germany
| | - T Gaspar
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Piorkowski
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Wechselberger
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - A Zedda
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Tomala
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - J Mayer
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - M Wagner
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - S Ulbrich
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - U Richter
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - Y Huo
- Heart Center - University Hospital Dresden, Dresden, Germany
| | - C Piorkowski
- Heart Center - University Hospital Dresden, Dresden, Germany
| |
Collapse
|
13
|
Effendy I, Mayer J, Nenoff P, Reinel D, Schaller M. Kombinationstherapie von schweren Onychomykosen – Empfehlungen eines Expertengremiums. Aktuelle Dermatologie 2020. [DOI: 10.1055/a-1150-0809] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
ZusammenfassungOnychomykosen sind schwer behandelbare Pilzinfektionen des Nagelorgans mit einer hohen Rezidivrate. Klinische Studien zeigen, dass bei gesicherter schwerer Nagelmykose durch Dermatophyten eine Steigerung der kompletten Heilungsrate (mykologisch plus klinisch) durch eine Kombinationsbehandlung mit lokal applizierten und oral verabreichten Antimykotika im Vergleich zur systemischen Monotherapie erreicht werden kann. Am besten untersucht sind Regime mit kontinuierlich täglicher Einnahme von Terbinafin und wöchentlicher Applikation eines Amorolfin-haltigen Nagellacks. Eine topische Monotherapie mit einem Nagellack kommt v. a. bei einer superfiziellen weißen Onychomykose (SWO) oder einer distal-subungualen Onychomykose (DSO) mit einem geringeren Befallsgrad ohne Beteiligung der Matrix infrage. Die mechanische Entfernung des infizierten Nagelmaterials und hygienische Maßnahmen unterstützen die Therapie. Kritisch für die Erfolgsaussichten ist eine hohe Langzeitadhärenz der Patienten. Die Therapie sollte bis zum Auftreten der Erscheinungsfreiheit andauern. Anschließend empfiehlt sich eine dauerhafte Rezidivprophylaxe mit antimykotischem Nagellack.
Collapse
Affiliation(s)
- I. Effendy
- Hautklinik, Klinikum der Stadt Bielefeld
| | | | - P. Nenoff
- Labor für medizinische Mikrobiologie, Rötha
| | - D. Reinel
- Dermatologische Praxis Dr. med. Gagu-Koll, Dr. med. Reinel, Hamburg
| | | |
Collapse
|
14
|
Revel A, Sorlin O, Marqués FM, Kondo Y, Kahlbow J, Nakamura T, Orr NA, Nowacki F, Tostevin JA, Yuan CX, Achouri NL, Al Falou H, Atar L, Aumann T, Baba H, Boretzky K, Caesar C, Calvet D, Chae H, Chiga N, Corsi A, Crawford HL, Delaunay F, Delbart A, Deshayes Q, Dombrádi Z, Douma CA, Elekes Z, Fallon P, Gašparić I, Gheller JM, Gibelin J, Gillibert A, Harakeh MN, He W, Hirayama A, Hoffman CR, Holl M, Horvat A, Horváth Á, Hwang JW, Isobe T, Kalantar-Nayestanaki N, Kawase S, Kim S, Kisamori K, Kobayashi T, Körper D, Koyama S, Kuti I, Lapoux V, Lindberg S, Masuoka S, Mayer J, Miki K, Murakami T, Najafi M, Nakano K, Nakatsuka N, Nilsson T, Obertelli A, de Oliveira Santos F, Otsu H, Ozaki T, Panin V, Paschalis S, Rossi D, Saito AT, Saito T, Sasano M, Sato H, Satou Y, Scheit H, Schindler F, Schrock P, Shikata M, Shimizu Y, Simon H, Sohler D, Stuhl L, Takeuchi S, Tanaka M, Thoennessen M, Törnqvist H, Togano Y, Tomai T, Tscheuschner J, Tsubota J, Uesaka T, Yang Z, Yasuda M, Yoneda K. Extending the Southern Shore of the Island of Inversion to ^{28}F. Phys Rev Lett 2020; 124:152502. [PMID: 32357034 DOI: 10.1103/physrevlett.124.152502] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 03/25/2020] [Accepted: 03/26/2020] [Indexed: 06/11/2023]
Abstract
Detailed spectroscopy of the neutron-unbound nucleus ^{28}F has been performed for the first time following proton/neutron removal from ^{29}Ne/^{29}F beams at energies around 230 MeV/nucleon. The invariant-mass spectra were reconstructed for both the ^{27}F^{(*)}+n and ^{26}F^{(*)}+2n coincidences and revealed a series of well-defined resonances. A near-threshold state was observed in both reactions and is identified as the ^{28}F ground state, with S_{n}(^{28}F)=-199(6) keV, while analysis of the 2n decay channel allowed a considerably improved S_{n}(^{27}F)=1620(60) keV to be deduced. Comparison with shell-model predictions and eikonal-model reaction calculations have allowed spin-parity assignments to be proposed for some of the lower-lying levels of ^{28}F. Importantly, in the case of the ground state, the reconstructed ^{27}F+n momentum distribution following neutron removal from ^{29}F indicates that it arises mainly from the 1p_{3/2} neutron intruder configuration. This demonstrates that the island of inversion around N=20 includes ^{28}F, and most probably ^{29}F, and suggests that ^{28}O is not doubly magic.
Collapse
Affiliation(s)
- A Revel
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Bvd Henri Becquerel, 14076 Caen, France
| | - O Sorlin
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Bvd Henri Becquerel, 14076 Caen, France
| | - F M Marqués
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - J Kahlbow
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - N A Orr
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - F Nowacki
- Université de Strasbourg, IPHC, 23 rue de Loess 67037 Strasbourg, France
- CNRS, UMR7178, 67037 Strasbourg, France
| | - J A Tostevin
- Department of Physics, University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom
| | - C X Yuan
- Sino-French Institute of Nuclear Engineering and Technology, Sun Yat-Sen University, Zhuhai 519082, China
| | - N L Achouri
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | | | - L Atar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - H Baba
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - D Calvet
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H Chae
- IBS, 55, Expo-ro, Yuseong-gu, Daejeon 34126, Korea
| | - N Chiga
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - A Corsi
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H L Crawford
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - F Delaunay
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - A Delbart
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Q Deshayes
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - Z Dombrádi
- Institute of Nuclear Research, Atomki, 4001 Debrecen, Hungary
| | - C A Douma
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - Z Elekes
- Institute of Nuclear Research, Atomki, 4001 Debrecen, Hungary
| | - P Fallon
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - I Gašparić
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Ruđer Bošković Institute, HR-10002 Zagreb, Croatia
| | - J-M Gheller
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Gibelin
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - A Gillibert
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M N Harakeh
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - W He
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - A Hirayama
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - C R Hoffman
- Physics Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Holl
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - A Horvat
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - Á Horváth
- Eötvös Loránd University, Pázmány Péter Sétány 1/A, H-1117 Budapest, Hungary
| | - J W Hwang
- Department of Physics and Astronomy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
| | - T Isobe
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | | | - S Kawase
- Department of Advanced Energy Engineering Science, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - S Kim
- Department of Physics and Astronomy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
| | - K Kisamori
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Kobayashi
- Department of Physics, Tohoku University, Miyagi 980-8578, Japan
| | - D Körper
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - S Koyama
- Unversity of Tokyo, Tokyo 1130033, Japan
| | - I Kuti
- Institute of Nuclear Research, Atomki, 4001 Debrecen, Hungary
| | - V Lapoux
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - S Lindberg
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - S Masuoka
- Center for Nuclear Study, University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J Mayer
- Institut für Kernphysik, Universität zu Köln, 50937 Köln, Germany
| | - K Miki
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Murakami
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Najafi
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - K Nakano
- Department of Advanced Energy Engineering Science, Kyushu University, Kasuga, Fukuoka 816-8580, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Nilsson
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - A Obertelli
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - F de Oliveira Santos
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Bvd Henri Becquerel, 14076 Caen, France
| | - H Otsu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - V Panin
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - D Rossi
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Saito
- Unversity of Tokyo, Tokyo 1130033, Japan
| | - M Sasano
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Satou
- Department of Physics and Astronomy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - F Schindler
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - P Schrock
- Center for Nuclear Study, University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - D Sohler
- Institute of Nuclear Research, Atomki, 4001 Debrecen, Hungary
| | - L Stuhl
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Takeuchi
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - M Tanaka
- Department of Physics, Osaka University, Osaka 560-0043, Japan
| | - M Thoennessen
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Törnqvist
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Tomai
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - J Tscheuschner
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Uesaka
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Z Yang
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Yasuda
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - K Yoneda
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
15
|
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:966-984. [PMID: 32127639 PMCID: PMC7214240 DOI: 10.1038/s41375-020-0776-2] [Citation(s) in RCA: 706] [Impact Index Per Article: 176.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Revised: 02/11/2020] [Accepted: 02/13/2020] [Indexed: 02/07/2023]
Abstract
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
Collapse
MESH Headings
- Aniline Compounds/therapeutic use
- Antineoplastic Agents/therapeutic use
- Clinical Decision-Making
- Consensus Development Conferences as Topic
- Dasatinib/therapeutic use
- Disease Management
- Fusion Proteins, bcr-abl/antagonists & inhibitors
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/metabolism
- Gene Expression
- Humans
- Imatinib Mesylate/therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Life Expectancy/trends
- Monitoring, Physiologic
- Nitriles/therapeutic use
- Protein Kinase Inhibitors/therapeutic use
- Pyrimidines/therapeutic use
- Quality of Life
- Quinolines/therapeutic use
- Survival Analysis
Collapse
Affiliation(s)
- A Hochhaus
- Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.
| | - M Baccarani
- Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy
| | - R T Silver
- Weill Cornell Medical College, New York, NY, USA
| | - C Schiffer
- Karmanos Cancer Center, Detroit, MI, USA
| | - J F Apperley
- Hammersmith Hospital, Imperial College, London, UK
| | | | - R E Clark
- Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - J E Cortes
- Georgia Cancer Center, Augusta University, Augusta, GA, USA
| | - M W Deininger
- Huntsman Cancer Center Salt Lake City, Salt Lake City, UT, USA
| | - F Guilhot
- Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - H Hjorth-Hansen
- Norwegian University of Science and Technology, Trondheim, Norway
| | - T P Hughes
- South Australian Health and Medical Research Institute, Adelaide, SA, Australia
| | - J J W M Janssen
- Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands
| | | | - D W Kim
- St. Mary´s Hematology Hospital, The Catholic University, Seoul, Korea
| | | | | | - F X Mahon
- Institut Bergonie, Université de Bordeaux, Bordeaux, France
| | - J Mayer
- Department of Internal Medicine, Masaryk University Hospital, Brno, Czech Republic
| | | | | | - F Pane
- Department Clinical Medicine and Surgery, University Federico Secondo, Naples, Italy
| | - J P Radich
- Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - D Rea
- Hôpital St. Louis, Paris, France
| | | | - G Rosti
- Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy
| | - P Rousselot
- Centre Hospitalier de Versailles, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France
| | - G Saglio
- University of Turin, Turin, Italy
| | - S Saußele
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - S Soverini
- Department of Hematology/Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy
| | | | - A Turkina
- National Research Center for Hematology, Moscow, Russian Federation
| | - A Zaritskey
- Almazov National Research Centre, St. Petersburg, Russian Federation
| | - R Hehlmann
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.
- ELN Foundation, Weinheim, Germany.
| |
Collapse
|
16
|
Cernan M, Szotkowski T, Hisemova M, Cetkovsky P, Sramkova L, Stary J, Racil Z, Mayer J, Sramek J, Jindra P, Visek B, Zak P, Novak J, Kozak T, Furst T, Papajik T. Blastic plasmacytoid dendritic cell neoplasm: First retrospective study in the Czech Republic. Neoplasma 2020; 67:650-659. [PMID: 32064883 DOI: 10.4149/neo_2020_190507n407] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 09/11/2019] [Indexed: 11/08/2022]
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive behavior and poor prognosis. We present the first retrospective analysis mapping its incidence and therapeutic outcomes in patients diagnosed and treated from 2000 to 2017 in the Czech Republic. The cohort comprised 14 patients (10 males, 4 females) with a median age at diagnosis of 39 years (range, 5-68 years). Initially, skin involvement was noted in 10 (71%) patients and bone marrow infiltration was present in 9 (64%). The first complete remission was achieved in 6/14 (43%) patients after acute lymphoblastic leukemia/lymphoma induction therapy and in 3/14 (21%) patients after acute myeloid leukemia regimen. Nine patients underwent allogeneic hematopoietic cell transplantation, with two patients achieving the first complete remission only after allogeneic transplantation. Patients undergoing allogeneic hematopoietic cell transplantation had longer overall survival than those treated without transplantation (the median survival over the period 16.4 vs. 8.1 months). Relapse of the disease was a significant predictor of mortality (p=0.05). Over the study period, patients' survival ranged from 3.3 to 44.2 months, with a median overall survival of 13 months. Our results revealed an effectivity of allogeneic hematopoietic cell transplantation on complete remission achievement in refractory/relapsed disease. The study aimed to present the actual data from the Czech Republic and thus contribute to a global understanding of BPDCN.
Collapse
Affiliation(s)
- M Cernan
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
| | - T Szotkowski
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
| | - M Hisemova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - P Cetkovsky
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - L Sramkova
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
| | - J Stary
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
| | - Z Racil
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - J Sramek
- Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech Republic
| | - P Jindra
- Department of Hemato-Oncology, University Hospital Pilsen, Pilsen, Czech Republic
| | - B Visek
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - P Zak
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - J Novak
- Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - T Kozak
- Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - T Furst
- Department of Mathematical Analysis and Application of Mathematics, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic
| | - T Papajik
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
| |
Collapse
|
17
|
Ulbrich S, Schoenbauer RS, Kirstein B, Tomala J, Huo Y, Mayer J, Richter U, Piorkowski J, Gaspar T, Mascherbauer J, Piorkowski C. P613Cardiac magnetic resonance imaging derived left ventricular mechanical function in patients with atrial fibrillation and left atrial low voltage zones. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The relation of left atrial low voltage zones (LVZ) to left ventricular function in patients undergoing pulmonary vein isolation (PVI) is not known.
Objective
To explore the relationship of left atrial low voltage zones (LVZ) on left ventricular function in patients with atrial fibrillation.
Methods
From June to Nov. 2018, 107 (mean age 67y, 70 men, 73 persistent AF) consecutive patients with symptomatic AF underwent a PVI with LVZ mapping. Before PVI the left ventricular ejection fraction (EF) and stroke volume (SV) were measured by cardiac magnetic resonance imaging (CMR). From feature-tracking of CMR-cine images left ventricular global, systolic and diastolic longitudinal strains (GLS), circumferential strains (GCS) and radial strains (GRS) were calculated.
Results
Of 59 patients CMR scanning in sinus rhythm was performed, LVZ were present in 24 patients.
LVEF was significantly lower in patients with left atrial LVZ (62±9% vs. 55±15%) (p=0,03). Left ventricular stroke volume was significantly decreased by the extent of LVZ (94±23 vs. 72±21ml), (p=0,03).
The left ventricular diastolic strains during ventricular filling (caused by atrial contraction) of GLS (r=−0,52), GCS (r=−0,65) and GRS (r=−0,65) were highly signifcantly correlated to the occurence and extent of LVZ (each p<0,001 respectively).
The only systolic ventricular strain was GLS, which decreased (r=−0,3, p=0,03) by the occurance of atrial low voltage.
Conclusion
The active, atrial part of diastolic left ventricular filling properties is impaired by the occurrence and extent of left atrial LVZ. In patients with left atrial LVZ the left ventricular stroke volume and ejection fraction is decreased already in sinus rhythm. It seems possible that atrial mechanical dysfunction and presence of atrial low voltage maybe predicted by LV diastolic strain analysis.
Collapse
Affiliation(s)
- S Ulbrich
- Dresden University of Technology, Heart Center, Dresden, Germany
| | | | - B Kirstein
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - J Tomala
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - Y Huo
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - J Piorkowski
- Dresden University of Technology, Heart Center, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center, Dresden, Germany
| | | | - C Piorkowski
- Dresden University of Technology, Heart Center, Dresden, Germany
| |
Collapse
|
18
|
Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW, Cerana S, Dictar MO, Bonvehi P, Tregnaghi JP, Fein L, Ashley D, Singh M, Hayes T, Playford G, Morrissey O, Thaler J, Kuehr T, Greil R, Pecherstorfer M, Duck L, Van Eygen K, Aoun M, De Prijck B, Franke FA, Barrios CHE, Mendes AVA, Serrano SV, Garcia RF, Moore F, Camargo JFC, Pires LA, Alves RS, Radinov A, Oreshkov K, Minchev V, Hubenova AI, Koynova T, Ivanov I, Rabotilova B, Minchev V, Petrov PA, Chilingirov P, Karanikolov S, Raynov J, Grimard D, McNeil S, Kumar D, Larratt LM, Weiss K, Delage R, Diaz-Mitoma FJ, Cano PO, Couture F, Carvajal P, Yepes A, Torres Ulloa R, Fardella P, Caglevic C, Rojas C, Orellana E, Gonzalez P, Acevedo A, Galvez KM, Gonzalez ME, Franco S, Restrepo JG, Rojas CA, Bonilla C, Florez LE, Ospina AV, Manneh R, Zorica R, Vrdoljak DV, Samarzija M, Petruzelka L, Vydra J, Mayer J, Cibula D, Prausova J, Paulson G, Ontaneda M, Palk K, Vahlberg A, Rooneem R, Galtier F, Postil D, Lucht F, Laine F, Launay O, Laurichesse H, Duval X, Cornely OA, Camerer B, Panse J, Zaiss M, Derigs HG, Menzel H, Verbeek M, Georgoulias V, Mavroudis D, Anagnostopoulos A, Terpos E, Cortes D, Umanzor J, Bejarano S, Galeano RW, Wong RSM, Hui P, Pedrazzoli P, Ruggeri L, Aversa F, Bosi A, Gentile G, Rambaldi A, Contu A, Marei L, Abbadi A, Hayajneh W, Kattan J, Farhat F, Chahine G, Rutkauskiene J, Marfil Rivera LJ, Lopez Chuken YA, Franco Villarreal H, Lopez Hernandez J, Blacklock H, Lopez RI, Alvarez R, Gomez AM, Quintana TS, Moreno Larrea MDC, Zorrilla SJ, Alarcon E, Samanez FCA, Caguioa PB, Tiangco BJ, Mora EM, Betancourt-Garcia RD, Hallman-Navarro D, Feliciano-Lopez LJ, Velez-Cortes HA, Cabanillas F, Ganea DE, Ciuleanu TE, Ghizdavescu DG, Miron L, Cebotaru CL, Cainap CI, Anghel R, Dvorkin MV, Gladkov OA, Fadeeva NV, Kuzmin AA, Lipatov ON, Zbarskaya II, Akhmetzyanov FS, Litvinov IV, Afanasyev BV, Cherenkova M, Lioznov D, Lisukov IA, Smirnova YA, Kolomietz S, Halawani H, Goh YT, Drgona L, Chudej J, Matejkova M, Reckova M, Rapoport BL, Szpak WM, Malan DR, Jonas N, Jung CW, Lee DG, Yoon SS, Lopez Jimenez J, Duran Martinez I, Rodriguez Moreno JF, Solano Vercet C, de la Camara R, Batlle Massana M, Yeh SP, Chen CY, Chou HH, Tsai CM, Chiu CH, Siritanaratkul N, Norasetthada L, Sriuranpong V, Seetalarom K, Akan H, Dane F, Ozcan MA, Ozsan GH, Kalayoglu Besisik SF, Cagatay A, Yalcin S, Peniket A, Mullan SR, Dakhil KM, Sivarajan K, Suh JJG, Sehgal A, Marquez F, Gomez EG, Mullane MR, Skinner WL, Behrens RJ, Trevarthe DR, Mazurczak MA, Lambiase EA, Vidal CA, Anac SY, Rodrigues GA, Baltz B, Boccia R, Wertheim MS, Holladay CS, Zenk D, Fusselman W, Wade III JL, Jaslowsk AJ, Keegan J, Robinson MO, Go RS, Farnen J, Amin B, Jurgens D, Risi GF, Beatty PG, Naqvi T, Parshad S, Hansen VL, Ahmed M, Steen PD, Badarinath S, Dekker A, Scouros MA, Young DE, Graydon Harker W, Kendall SD, Citron ML, Chedid S, Posada JG, Gupta MK, Rafiyath S, Buechler-Price J, Sreenivasappa S, Chay CH, Burke JM, Young SE, Mahmood A, Kugler JW, Gerstner G, Fuloria J, Belman ND, Geller R, Nieva J, Whittenberger BP, Wong BMY, Cescon TP, Abesada-Terk G, Guarino MJ, Zweibach A, Ibrahim EN, Takahashi G, Garrison MA, Mowat RB, Choi BS, Oliff IA, Singh J, Guter KA, Ayrons K, Rowland KM, Noga SJ, Rao SB, Columbie A, Nualart MT, Cecchi GR, Campos LT, Mohebtash M, Flores MR, Rothstein-Rubin R, O'Connor BM, Soori G, Knapp M, Miranda FG, Goodgame BW, Kassem M, Belani R, Sharma S, Ortiz T, Sonneborn HL, Markowitz AB, Wilbur D, Meiri E, Koo VS, Jhangiani HS, Wong L, Sanani S, Lawrence SJ, Jones CM, Murray C, Papageorgiou C, Gurtler JS, Ascensao JL, Seetalarom K, Venigalla ML, D'Andrea M, De Las Casas C, Haile DJ, Qazi FU, Santander JL, Thomas MR, Rao VP, Craig M, Garg RJ, Robles R, Lyons RM, Stegemoller RK, Goel S, Garg S, Lowry P, Lynch C, Lash B, Repka T, Baker J, Goueli BS, Campbell TC, Van Echo DA, Lee YJ, Reyes EA, Senecal FM, Donnelly G, Byeff P, Weiss R, Reid T, Roeland E, Goel A, Prow DM, Brandt DS, Kaplan HG, Payne JE, Boeckh MG, Rosen PJ, Mena RR, Khan R, Betts RF, Sharp SA, Morrison VA, Fitz-Patrick D, Congdon J, Erickson N, Abbasi R, Henderson S, Mehdi A, Wos EJ, Rehmus E, Beltzer L, Tamayo RA, Mahmood T, Reboli AC, Moore A, Brown JM, Cruz J, Quick DP, Potz JL, Kotz KW, Hutchins M, Chowhan NM, Devabhaktuni YD, Braly P, Berenguer RA, Shambaugh SC, O'Rourke TJ, Conkright WA, Winkler CF, Addo FEK, Duic JP, High KP, Kutner ME, Collins R, Carrizosa DR, Perry DJ, Kailath E, Rosen N, Sotolongo R, Shoham S, Chen T. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. The Lancet Infectious Diseases 2019; 19:1001-1012. [DOI: 10.1016/s1473-3099(19)30310-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 05/02/2019] [Accepted: 05/03/2019] [Indexed: 12/25/2022]
|
19
|
Jacobsen E, Ďuraš J, Ardeshna K, Cherry M, Offner F, Mayer J, Bijou F, Tani M, Musuraca G, Merli M, Marasca R, Weaver D, Lustgarten S, Youssoufian H, Zinzani P. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.70_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E. Jacobsen
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - J. Ďuraš
- University Hospital Ostrava and Faculty of Medicine; University Hospital Ostrava; Ostrava Czech Republic
| | - K. Ardeshna
- Department of Oncology; University College London Hospitals National Health Service Foundation Trust; London United Kingdom
| | - M. Cherry
- Department of Medical Oncology; Atlantic Health Systems; Morristown NJ United States
| | - F. Offner
- Department of Hematology; University Hospital Ghent; Gent Belgium
| | - J. Mayer
- Department of Internal Medicine; Fakultní Nemocnice Brno; Brno Czech Republic
| | - F. Bijou
- Department of Medical Oncology; Institut Bergonie; Boredeaux France
| | - M. Tani
- Hematology Unit; Santa Maria delle Croci Hospital; Ravenna Italy
| | - G. Musuraca
- Hematology Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori; Meldola Italy
| | - M. Merli
- Department of Hematology; Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - R. Marasca
- Department of Medical Sciences; Section of Hematology, Università di Modena e Reggio Emilia; Modena Italy
| | - D.T. Weaver
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - S. Lustgarten
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - H. Youssoufian
- Medical Affairs; Verastem Oncology; Needham MA United States
| | - P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| |
Collapse
|
20
|
Hadrabova M, Janikova A, Hrncirikova I, Svobodová Z, Mala A, Kapounkova K, Mayer J. SYMPATHOVAGAL IMBALANCE IN LYMPHOMA PATIENTS CAN BE RESTORED BY PHYSICAL TRAINING - SINGLE CENTRE PROSPECTIVE TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.233_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Hadrabova
- Dpt. of Hematology; Oncology and Internal Medicine, University Hospital Brno; Brno Czech Republic
| | - A. Janikova
- Dpt. of Hematology; Oncology and Internal Medicine, University Hospital Brno; Brno Czech Republic
| | - I. Hrncirikova
- Dpt. of Health Promotion; Masaryk University Brno/Faculty of Sports; Brno Czech Republic
| | - Z. Svobodová
- Dpt. of Health Promotion; Masaryk University Brno/Faculty of Sports; Brno Czech Republic
| | - A. Mala
- Dpt. of Health Promotion; Masaryk University Brno/Faculty of Sports; Brno Czech Republic
| | - K. Kapounkova
- Dpt. of Health Promotion; Masaryk University Brno/Faculty of Sports; Brno Czech Republic
| | - J. Mayer
- Dpt. of Hematology; Oncology and Internal Medicine, University Hospital Brno; Brno Czech Republic
| |
Collapse
|
21
|
Wang M, Belada D, Cheah C, Chu M, Dreyling M, Flinn I, Fogliatto L, Goy A, Inwards D, Jurczak W, Mayer J, Re F, Robak T, Spurgeon S, Yoon S, Zinzani P, Yin M, Chen T, Kahl B. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M. Wang
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston United States
| | - D. Belada
- Charles University Hospital and Faculty of Medicine; Fourth Department of Internal Medicine-Hematology; Hradec Králové Czech Republic
| | - C. Cheah
- Comprehensive Cancer Centre; Sir Charles Gairdner Hospital; Nedlands WA Australia
| | - M.P. Chu
- Clinician Scientist; Cross Cancer Institute; Edmonton Canada
| | - M. Dreyling
- Medizinische Klinik und Poliklinik III; Klinikum der Universität München, LMU München; München Germany
| | - I. Flinn
- Lymphoma Research; Sarah Cannon; Nashville United States
| | - L. Fogliatto
- Hematology; Irmandade da Santa Case de Misericórdia; Porto Alegre Brazil
| | - A. Goy
- Lymphoma Division; John Theurer Cancer Center, Hackensack University Medical Center; Hackensack United States
| | - D. Inwards
- Hematology; Mayo Clinic; Rochester United States
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Mayer
- Hematology; Fakultní nemocnice Brno; Brno Czech Republic
| | - F. Re
- Hematology; Azienda Ospedaliero-Universitaria di Parma; Parma Italy
| | - T. Robak
- Hematology; Medical University of Lodz, Copernicus Memorial Hospital; Lodz Poland
| | - S. Spurgeon
- Hematology and Medical Oncology; OHSU Knight Cancer Institute; Portland United States
| | - S.S. Yoon
- Hemato Oncology; Seoul National University Hospital; Seoul Republic of Korea
| | - P.L. Zinzani
- Hematology; Institute of Hematology Seràgnoli, University of Bologna; Bologna Italy
| | - M. Yin
- Bio statistics; Acerta Pharma; South San Francisco United States
| | - T. Chen
- Clinical Development; Acerta Pharma; South San Francisco United States
| | | | | |
Collapse
|
22
|
Durinikova A, Folta A, Culen M, Kosarova Z, Tom N, Al Tukmachi D, Cetkovsky P, Jindra P, Szotkowski T, Zak P, Mayer J, Racil Z, Jeziskova I. PF247 CONSEQUENCES OF NRAS MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000559204.24910.9e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
23
|
Salek D, Janikova A, Michalka J, Miculkova E, Hadrabova M, Folber F, Kral Z, Mayer J. FIRST-LINE ADJUVANT RADIOTHERAPY IMPROVES PFS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA - A RETROSPECTIVE ANALYSIS OF 102 PATIENTS FROM A SINGLE CENTER. Hematol Oncol 2019. [DOI: 10.1002/hon.134_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Salek
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - A. Janikova
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - J. Michalka
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - E. Miculkova
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - M. Hadrabova
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - F. Folber
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - Z. Kral
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| | - J. Mayer
- Department of Internal Medicine; Hematology and Oncology, University Hospital Brno; Brno Czech Republic
| |
Collapse
|
24
|
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 2019; 33:969-980. [PMID: 30315239 PMCID: PMC6484712 DOI: 10.1038/s41375-018-0276-9] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 05/09/2018] [Accepted: 08/28/2018] [Indexed: 12/21/2022]
Abstract
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for placebo+BR (hazard ratio [HR] [95% CI], 0.206 [0.159-0.265]; P < 0.0001); 36-month PFS rates were 68.0% versus 13.9%, respectively. The results are consistent with the primary analysis findings (HR = 0.203, as assessed by independent review committee, with 17-month median follow-up). Median overall survival was not reached in either arm; HR (95% CI) for ibrutinib+BR versus placebo: 0.652 (0.454-0.935; P = 0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for ibrutinib+BR and 6.2% for placebo+BR (P < 0.0001). Incidence of treatment-emergent adverse events (including grades 3-4) were generally consistent with the initial HELIOS report. These long-term data support improved survival outcomes and deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL.
Collapse
Affiliation(s)
- G Fraser
- Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
| | - P Cramer
- Department of Internal Medicine, Center of Integrated Oncology and German CLL Study Group, University of Cologne, Cologne, Germany
| | - F Demirkan
- Division of Hematology, Dokuz Eylul University, Izmir, Turkey
| | - R Santucci Silva
- IEP São Lucas/Hemomed Oncologia e Hematologia, São Paulo, Brazil
| | - S Grosicki
- Department of Cancer Prevention, Faculty of Public Health, Silesian Medical University, Katowice, Poland
| | - A Pristupa
- Regional Clinical Hospital, Ryazan, Russia
| | - A Janssens
- Universitaire Ziekenhuizen Leuven, Leuven, Belgium
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Jihlavska, Brno, Czech Republic
| | - N L Bartlett
- Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
| | | | - H Pylypenko
- Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine
| | - J Loscertales
- Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain
| | - A Avigdor
- Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel
| | - S Rule
- Department of Haematology, Plymouth University Medical School, Plymouth, UK
| | - D Villa
- Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - O Samoilova
- Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia
| | - P Panagiotidis
- 1st Department of Propedeutic Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - A Goy
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
| | - M A Pavlovsky
- Department of Hematology, Fundaleu, Buenos Aires, Argentina
| | - C Karlsson
- Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - M Hallek
- Department I of Internal Medicine, University of Cologne, Cologne, Germany
| | - M Mahler
- Janssen Research & Development, Raritan, NJ, USA
| | - M Salman
- Janssen Research & Development, Raritan, NJ, USA
| | - S Sun
- Janssen Research & Development, Raritan, NJ, USA
| | - C Phelps
- Janssen Research & Development, Raritan, NJ, USA
| | | | - A Howes
- Janssen Research & Development, High Wycombe, UK
| | | |
Collapse
|
25
|
Ran K, Deibert W, Ivanova ME, Meulenberg WA, Mayer J. Crystal structure investigation of La 5.4W 1-yMo yO 12-δ for gas separation by high-resolution transmission electron microscopy. Sci Rep 2019; 9:3274. [PMID: 30824737 PMCID: PMC6397252 DOI: 10.1038/s41598-019-39758-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 01/30/2019] [Indexed: 11/29/2022] Open
Abstract
Lanthanum tungstate (LWO) and LWO with 20 at.% and 35 at.% molybdenum substituting tungsten were prepared by the Pechini method. Phase purity and successful Mo substitution inside these dense LWO membrane materials were confirmed by conventional and high resolution transmission electron microscopy techniques. The split of La2/W2 site by around 0.3 Å was proven. Extra reflections show up in the diffraction patterns from Mo-substituted LWO, and together with simulations, these reflections were recognized as forbidden reflections in a non-substituted LWO system, while the extinction rules are broken by Mo substitution due to the different scattering factors of W and Mo. Energy-dispersive X-ray chemical mapping allowed direct visualization of individual atomic columns, and revealed that all Mo is located at the W1 sites in the Mo-substituted LWO. Moreover, the diffuse scattering in diffraction patterns provides direct evidence of short range clustering of oxygen vacancies and could be further related to the oxygen conduction of the LWO membranes.
Collapse
Affiliation(s)
- K Ran
- Central Facility for Electron Microscopy GFE, RWTH Aachen University, 52074, Aachen, Germany. .,Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons ER-C, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
| | - W Deibert
- Institute of Energy and Climate Research IEK-1, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - M E Ivanova
- Institute of Energy and Climate Research IEK-1, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - W A Meulenberg
- Institute of Energy and Climate Research IEK-1, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.,Faculty of Science and Technology, Inorganic Membranes, Universtiy of Twente, 7500 AE, Enschede, The Netherlands
| | - J Mayer
- Central Facility for Electron Microscopy GFE, RWTH Aachen University, 52074, Aachen, Germany.,Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons ER-C, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| |
Collapse
|
26
|
Wang ZC, Zhong XY, Jin L, Chen XF, Moritomo Y, Mayer J. Retraction notice to "Effects of dynamic diffraction conditions on magnetic parameter determination in a double perovskite Sr 2FeMoO 6 using electron energy-loss magnetic chiral dichroism" [Ultramicroscopy 176, 2017, pp. 212-217]. Ultramicroscopy 2018:S0304-3991(18)30397-8. [PMID: 30527954 DOI: 10.1016/j.ultramic.2018.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 11/23/2018] [Indexed: 10/27/2022]
Affiliation(s)
- Z C Wang
- National Center for Electron Microscopy in Beijing, Key Laboratory of Advanced Materials (MOE), The State Key Laboratory of New Ceramics and Fine Processing, School of Materials Science and Engineering, Tsinghua University, Beijing 100084, China
| | - X Y Zhong
- National Center for Electron Microscopy in Beijing, Key Laboratory of Advanced Materials (MOE), The State Key Laboratory of New Ceramics and Fine Processing, School of Materials Science and Engineering, Tsinghua University, Beijing 100084, China
| | - L Jin
- Peter Grünberg Institute and Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons (ER-C), Forschungszentrum Jülich, 52425 Jülich, Germany
| | - X F Chen
- National Center for Electron Microscopy in Beijing, Key Laboratory of Advanced Materials (MOE), The State Key Laboratory of New Ceramics and Fine Processing, School of Materials Science and Engineering, Tsinghua University, Beijing 100084, China
| | - Y Moritomo
- Graduate School of Pure & Applied Science and Faculty of Pure & Applied Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-7571, Japan
| | - J Mayer
- Peter Grünberg Institute and Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons (ER-C), Forschungszentrum Jülich, 52425 Jülich, Germany; Central Facility for Electron Microscopy, RWTH Aachen University, 52074 Aachen, Germany
| |
Collapse
|
27
|
Cavalli F, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Robak T. Final overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Kubiak M, Solarczek J, Mayer J, Kampen I, Biedendieck R, Schallmey A, Schilde C. Struktur-Eigenschaftsbeziehung bei der Aufarbeitung und Formulierung von Proteinpartikeln. CHEM-ING-TECH 2018. [DOI: 10.1002/cite.201855444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Kubiak
- Technische Universität Braunschweig; Institut für Partikeltechnik; Volkmaroder Straße 5 38104 Braunschweig Deutschland
- Technische Universität Braunschweig; Zentrum für Pharmaverfahrenstechnik; Franz-Liszt-Straße 35 A 38106 Braunschweig Deutschland
| | - J. Solarczek
- Technische Universität Braunschweig; Institut für Biochemie; Spielmannstraße 7 38106 Braunschweig Deutschland
| | - J. Mayer
- Technische Universität Braunschweig; Institut für Mikrobiologie; Spielmannstraße 7 38106 Braunschweig Deutschland
| | - I. Kampen
- Technische Universität Braunschweig; Institut für Partikeltechnik; Volkmaroder Straße 5 38104 Braunschweig Deutschland
- Technische Universität Braunschweig; Zentrum für Pharmaverfahrenstechnik; Franz-Liszt-Straße 35 A 38106 Braunschweig Deutschland
| | - R. Biedendieck
- Technische Universität Braunschweig; Institut für Mikrobiologie; Spielmannstraße 7 38106 Braunschweig Deutschland
| | - A. Schallmey
- Technische Universität Braunschweig; Institut für Biochemie; Spielmannstraße 7 38106 Braunschweig Deutschland
| | - C. Schilde
- Technische Universität Braunschweig; Institut für Partikeltechnik; Volkmaroder Straße 5 38104 Braunschweig Deutschland
- Technische Universität Braunschweig; Zentrum für Pharmaverfahrenstechnik; Franz-Liszt-Straße 35 A 38106 Braunschweig Deutschland
| |
Collapse
|
29
|
Mayer J, Günther G, Pippel J, Lauermann A, Kubiak M, Schilde C, Blankenfeldt W, Biedendieck R. Crystal structures and characterization of different thermostable Penicillin G acylases (PGAs) from Gram-positive bacteria. CHEM-ING-TECH 2018. [DOI: 10.1002/cite.201855320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Mayer
- TU Braunschweig; Institute of Microbiology and BRICS; Rebenring 56 38106 Braunschweig Germany
| | - G. Günther
- TU Braunschweig; Institute of Microbiology and BRICS; Rebenring 56 38106 Braunschweig Germany
| | - J. Pippel
- Helmholtz Centre for Infection Research; Structure and Function of Proteins; Inhoffenstraße 7 38124 Braunschweig Germany
| | - A. Lauermann
- TU Braunschweig; Institute of Microbiology and BRICS; Rebenring 56 38106 Braunschweig Germany
| | - M. Kubiak
- TU Braunschweig; Institute for Particle Technology; Volkmaroder Straße 5 38104 Braunschweig Germany
| | - C. Schilde
- TU Braunschweig; Institute for Particle Technology; Volkmaroder Straße 5 38104 Braunschweig Germany
| | - W. Blankenfeldt
- Helmholtz Centre for Infection Research; Structure and Function of Proteins; Inhoffenstraße 7 38124 Braunschweig Germany
| | - R. Biedendieck
- TU Braunschweig; Institute of Microbiology and BRICS; Rebenring 56 38106 Braunschweig Germany
| |
Collapse
|
30
|
Aretz A, Ehle L, Haeusler A, Bobzin K, Öte M, Wiesner S, Schmidt A, Gillner A, Poprawe R, Mayer J. In situ investigation of production processes in a large chamber scanning electron microscope. Ultramicroscopy 2018; 193:151-158. [PMID: 30075368 DOI: 10.1016/j.ultramic.2018.07.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Revised: 06/27/2018] [Accepted: 07/03/2018] [Indexed: 11/17/2022]
Abstract
A large-chamber scanning electron microscope (LC-SEM) provides an ideal platform for the installation of large-scale in situ experiments. Our LC-SEM has internal chamber dimensions of 1,2 × 1,3 × 1,4 m3 (W × H × D) (Fig.1) and makes it possible to incorporate novel in situ experimental devices, which are reported on here. The present manuscript describes in detail the development of in situ test equipment for the study of a broad range of processes in production engineering. Direct observation of the materials modification mechanisms provides fundamental insight into the underlying process characteristics. An in situ turning device was developed, tested and used to observe the chip formation on the microstructure scale of a 43CrMo4-sample. Laser beam micro welding was integrated into the LC-SEM to achieve in situ analysis of the welding process on stainless steel 1.4310. A heating module was employed for in situ wetting experiments to observe the formation and solidification of the melt of a tin-copper brazing filler on an aluminium cast alloy.
Collapse
Affiliation(s)
- A Aretz
- Central Facility for Electron Microscopy, RWTH Aachen University, Ahornstr. 55, 52074, Aachen, Germany
| | - L Ehle
- Central Facility for Electron Microscopy, RWTH Aachen University, Ahornstr. 55, 52074, Aachen, Germany
| | - A Haeusler
- Chair for Laser Technology LLT, RWTH Aachen University, Steinbachstr. 15, 52074, Aachen, Germany
| | - K Bobzin
- Surface Engineering Institute, RWTH Aachen University, Kackertstr. 15, 52072, Aachen, Germany
| | - M Öte
- Surface Engineering Institute, RWTH Aachen University, Kackertstr. 15, 52072, Aachen, Germany
| | - S Wiesner
- Surface Engineering Institute, RWTH Aachen University, Kackertstr. 15, 52072, Aachen, Germany
| | - A Schmidt
- Surface Engineering Institute, RWTH Aachen University, Kackertstr. 15, 52072, Aachen, Germany
| | - A Gillner
- Chair for Laser Technology LLT, RWTH Aachen University, Steinbachstr. 15, 52074, Aachen, Germany
| | - R Poprawe
- Chair for Laser Technology LLT, RWTH Aachen University, Steinbachstr. 15, 52074, Aachen, Germany
| | - J Mayer
- Central Facility for Electron Microscopy, RWTH Aachen University, Ahornstr. 55, 52074, Aachen, Germany.
| |
Collapse
|
31
|
Kornet‐van der Aa DA, van Randeraad‐van der Zee CH, Mayer J, Borys JM, Chinapaw MJM. Recommendations for obesity prevention among adolescents from disadvantaged backgrounds: a concept mapping study among scientific and professional experts. Pediatr Obes 2018; 13:389-392. [PMID: 28921882 PMCID: PMC6001431 DOI: 10.1111/ijpo.12239] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 07/25/2017] [Accepted: 08/05/2017] [Indexed: 01/11/2023]
Abstract
The present study aimed to enrich the scientific evidence on obesity prevention programmes for adolescents from socio-economically disadvantaged backgrounds with practice-based experiences from both scientific and professional experts in the field of youth obesity prevention. We used the participatory method of concept mapping. Two concept mapping sessions were conducted: one with programme coordinators of national/regional obesity prevention programmes across Europe (n = 8) and one with scientists participating in European obesity prevention projects (n = 5). Five recommendations were extracted from both concept maps: (1) involve adolescents in the design and delivery of the programme, (2) invest in family/parental capacity building, (3) provide and support a healthy school food and physical activity environment, (4) regulate exposure to unhealthy messages/advertising and (5) facilitate safe and active travel. These recommendations can be used as a conceptual framework for programme development for preventing obesity in adolescents.
Collapse
Affiliation(s)
- D. A. Kornet‐van der Aa
- Department of Public and Occupational Health, Amsterdam Public Health research instituteVU University Medical CenterAmsterdamThe Netherlands
| | - C. H. van Randeraad‐van der Zee
- Department of Public and Occupational Health, Amsterdam Public Health research instituteVU University Medical CenterAmsterdamThe Netherlands
| | | | | | - M. J. M. Chinapaw
- Department of Public and Occupational Health, Amsterdam Public Health research instituteVU University Medical CenterAmsterdamThe Netherlands
| |
Collapse
|
32
|
Zühlke A, Bergner M, Entezami M, Schneider U, Mayer J, Tchirikov M. Anwendung der ultradünnen fetoskopischen Technik reduziert die Verletzung der amnialen Membran und verbessert das neonatale Outcome beim TTTS (ClinicalTrials.gov: NCT03151915). Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1645892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- A Zühlke
- Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Geburtshilfe und Pränatalmedizin, Zentrum für Fetalchirurgie
| | - M Bergner
- Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Geburtshilfe und Pränatalmedizin, Zentrum für Fetalchirurgie
| | - M Entezami
- Zentrum für Pränataldiagnostik und Humangenetik, Kurfürstendamm199, Berlin
| | - U Schneider
- Universitätsklinikum Jena, Klinik für Geburtshilfe
| | - J Mayer
- Klinikum Sindelfingen-Böblingen, Zentrum für Frauenheilkunde und Geburtshilfe
| | - M Tchirikov
- Universitätsklinikum Halle (Saale), Universitätsklinik und Poliklinik für Geburtshilfe und Pränatalmedizin, Zentrum für Fetalchirurgie
| |
Collapse
|
33
|
Richter U, Kronburg MB, Huo Y, Sitzy J, Pu L, Mayer J, Ulbrich S, Gaspar T, Piorkowski C. P1214From trials to clinical practice: True outcome of AF landmark trials and studies. Europace 2018. [DOI: 10.1093/europace/euy015.696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- U Richter
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - M B Kronburg
- Aarhus University Hospital, Electrophysiology, Aarhus, Denmark
| | - Y Huo
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - J Sitzy
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - L Pu
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - J Mayer
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - S Ulbrich
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - T Gaspar
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - C Piorkowski
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| |
Collapse
|
34
|
Huo Y, Kronborg MB, Ulbrich S, Zedda A, Mayer J, Pu L, Guo J, Richter U, Sitzy J, Gaspar T, Piorkowski C. P364Presence of low voltage zone areas is associated with lower AF recurrence in patients undergoing re-ablation with substrate modification. Europace 2018. [DOI: 10.1093/europace/euy015.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y Huo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - M B Kronborg
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - S Ulbrich
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - A Zedda
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - L Pu
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Guo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Sitzy
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - C Piorkowski
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| |
Collapse
|
35
|
Huo Y, Kronborg MB, Ulbrich S, Zedda A, Mayer J, Pu L, Guo J, Richter U, Sitzy J, Gaspar T, Piorkowski C. P1170Freedom from AF after total left atrial isolation in patients with large areas arrhythmia substrate. Europace 2018. [DOI: 10.1093/europace/euy015.655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Huo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - M B Kronborg
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - S Ulbrich
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - A Zedda
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - L Pu
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Guo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Sitzy
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - C Piorkowski
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| |
Collapse
|
36
|
Ulbrich S, Huo Y, Richter U, Mayer J, Pu L, Kronborg MB, Zedda AM, Guo J, Sitzy J, Gaspar T, Piorkowski C. P836Mechanical function after total left atrial isolation in patients with atrial fibrillation at the end stage of left atrial myopathy. Europace 2018. [DOI: 10.1093/europace/euy015.440] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Ulbrich
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - Y Huo
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - L Pu
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - M B Kronborg
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - A M Zedda
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - J Guo
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - J Sitzy
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| | - C Piorkowski
- Dresden University of Technology, Heart Center, Department of Cardiology and Intensive Care, Dresden, Germany
| |
Collapse
|
37
|
Huo Y, Kronborg MB, Ulbrich S, Zedda AM, Mayer J, Pu L, Guo J, Richter U, Sitzy J, Gaspar T, Piorkowski C. P840Feasibility and safety of total left atrial isolation and subsequent left atrial appendage occlusion in the patients with atrial fibrillation at the end stage of left atrial myopathy. Europace 2018. [DOI: 10.1093/europace/euy015.443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Huo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - M B Kronborg
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - S Ulbrich
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - A M Zedda
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - L Pu
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Guo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Sitzy
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - C Piorkowski
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| |
Collapse
|
38
|
Richter U, Kronborg MB, Huo Y, Sitzy J, Mayer J, Ulbrich S, Pu L, Gaspar T, Piorkowski C. 48Succses of atrial fibrillation ablation in patients with paroxsysmal or persistent AF when comparing continuous with periodic discontinuous continuous follow-up. Europace 2018. [DOI: 10.1093/europace/euy015.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- U Richter
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - M B Kronborg
- Aarhus University Hospital, Electrophysiology, Aarhus, Denmark
| | - Y Huo
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - J Sitzy
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - J Mayer
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - S Ulbrich
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - L Pu
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - T Gaspar
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| | - C Piorkowski
- University Hospital Dresden, Electrophysiology, Dresden, Germany
| |
Collapse
|
39
|
Huo Y, Kronborg MB, Sitzy J, Richter U, Mayer J, Ulbrich S, Pu L, Gaspar T, Piorkowski C. P277Changes in left atrium voltage map characteristics in patients undergoing re-ablation for atrial fibrillation. Europace 2018. [DOI: 10.1093/europace/euy015.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y Huo
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - M B Kronborg
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Sitzy
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - U Richter
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - J Mayer
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - S Ulbrich
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - L Pu
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - T Gaspar
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| | - C Piorkowski
- Dresden University of Technology, Heart Center University Hospital, Dresden, Germany
| |
Collapse
|
40
|
Witzig T, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa L, Bermudez Silva C, Zhu J, Belada D, Bouabdallah K, Kattan J, Kuruvilla J, Kim W, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol 2018; 29:707-714. [DOI: 10.1093/annonc/mdx764] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Rodenbücher C, Meuffels P, Bihlmayer G, Speier W, Du H, Schwedt A, Breuer U, Jia CL, Mayer J, Waser R, Szot K. Electrically controlled transformation of memristive titanates into mesoporous titanium oxides via incongruent sublimation. Sci Rep 2018; 8:3774. [PMID: 29491379 PMCID: PMC5830621 DOI: 10.1038/s41598-018-22238-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Accepted: 02/20/2018] [Indexed: 11/11/2022] Open
Abstract
Perovskites such as SrTiO3, BaTiO3, and CaTiO3 have become key materials for future energy-efficient memristive data storage and logic applications due to their ability to switch their resistance reversibly upon application of an external voltage. This resistance switching effect is based on the evolution of nanoscale conducting filaments with different stoichiometry and structure than the original oxide. In order to design and optimize memristive devices, a fundamental understanding of the interaction between electrochemical stress, stoichiometry changes and phase transformations is needed. Here, we follow the approach of investigating these effects in a macroscopic model system. We show that by applying a DC voltage under reducing conditions on a perovskite slab it is possible to induce stoichiometry polarization allowing for a controlled decomposition related to incongruent sublimation of the alkaline earth metal starting in the surface region. This way, self-formed mesoporous layers can be generated which are fully depleted by Sr (or Ba, Ca) but consist of titanium oxides including TiO and Ti3O with tens of micrometre thickness. This illustrates that phase transformations can be induced easily by electrochemical driving forces.
Collapse
Affiliation(s)
- C Rodenbücher
- Peter Grünberg Institute, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany.
| | - P Meuffels
- Peter Grünberg Institute, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - G Bihlmayer
- Peter Grünberg Institute, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- Institute of Advanced Simulation, Forschungszentrum Jülich, 52425, Jülich, Germany
| | - W Speier
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - H Du
- Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- Gemeinschaftslabor für Elektronenmikroskopie, RWTH Aachen, 52056, Aachen, Germany
| | | | - U Breuer
- Central Institute for Engineering, Electronics and Analytics, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - C-L Jia
- Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
| | - J Mayer
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- Ernst Ruska-Centre for Microscopy and Spectroscopy with Electrons, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- Gemeinschaftslabor für Elektronenmikroskopie, RWTH Aachen, 52056, Aachen, Germany
| | - R Waser
- Peter Grünberg Institute, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- Institut für Werkstoffe der Elektrotechnik 2, RWTH Aachen, 52056, Aachen, Germany
| | - K Szot
- Peter Grünberg Institute, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- JARA - Fundamentals of Future Information Technologies, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany
- A. Chełkowski Institute of Physics, University of Silesia, 40-007, Katowice, Poland
| |
Collapse
|
42
|
Mantziki K, Renders CM, Westerman MJ, Mayer J, Borys JM, Seidell JC. Tools for a systematic appraisal of integrated community-based approaches to prevent childhood obesity. BMC Public Health 2018; 18:189. [PMID: 29378550 PMCID: PMC5789618 DOI: 10.1186/s12889-018-5042-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 01/05/2018] [Indexed: 01/04/2023] Open
Abstract
Background Evaluation and monitoring methods are often unable to identify crucial elements of success or failure of integrated community-wide approaches aiming to tackle childhood overweight and obesity, yet difficult to determine in complex programmes. Therefore, we aimed to systematically appraise strengths and weaknesses of such programmes and to assess the usefulness of the appraisal tools used. Methods To identify strengths and weaknesses of the integrated community-based approaches two tools were used: the Good Practice Appraisal tool for obesity prevention programmes, projects, initiatives and intervention (GPAT), a self-administered questionnaire developed by the WHO; and the OPEN tool, a structured list of questions based on the EPODE theory, to assist face-to-face interviews with the principle programme coordinators. The strengths and weaknesses of these tools were assessed with regard to practicalities, quality of acquired data and the appraisal process, criteria and scoring. Results Several strengths and weaknesses were identified in all the assessed integrated community-based approaches, different for each of them. The GPAT provided information mostly on intervention elements whereas through the OPEN tool information on both the programme and intervention levels were acquired. Conclusion Large variability between integrated community-wide approaches preventing childhood obesity in the European region was identified and therefore each of them has different needs. Both tools used in combination seem to facilitate comprehensive assessment of integrated community-wide approaches in a systematic manner, which is rarely conducted. Nonetheless, the tools should be improved in line to their limitations as recommended in this manuscript. Electronic supplementary material The online version of this article (10.1186/s12889-018-5042-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- K Mantziki
- Department of Health Sciences, VU University of Amsterdam, De Boelelaan 1085, 1081HV, Amsterdam, The Netherlands.
| | - C M Renders
- Department of Health Sciences, VU University of Amsterdam, De Boelelaan 1085, 1081HV, Amsterdam, The Netherlands
| | - M J Westerman
- Department of Health Sciences, VU University of Amsterdam, De Boelelaan 1085, 1081HV, Amsterdam, The Netherlands
| | - J Mayer
- EPODE International Network, 109-111 Rue Royale, 1000, Brussels, Belgium
| | - J M Borys
- EPODE International Network, 109-111 Rue Royale, 1000, Brussels, Belgium
| | - J C Seidell
- Department of Health Sciences, VU University of Amsterdam, De Boelelaan 1085, 1081HV, Amsterdam, The Netherlands
| |
Collapse
|
43
|
Langhoff J, Mayer J, Faber L, Kaestner S, Guibert G, Zlinszky K, Auer JA, Rechenberg BV. Does surface anodisation of titanium implants change osseointegration and make their extraction from bone any easier? Vet Comp Orthop Traumatol 2018. [DOI: 10.1055/s-0037-1617362] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Objectives: Titanium implants have a tendency for high bone-implant bonding, and, in comparison to stainless steel implants are more difficult to remove. The current study was carried out to evaluate, i) the release strength of three selected anodized titanium surfaces with increased nanohardness and low roughness, and ii) bone-implant bonding in vivo. These modified surfaces were intended to give improved anchorage while facilitating easier removal of temporary implants. Material and methods: The new surfaces were referenced to a stainless steel implant and a standard titanium implant surface (TiMAX™). In a sheep limb model, healing period was 3 months. Bone-implant bonding was evaluated either biomechanically or histologically. Results: The new surface anodized screws demonstrated similar or slightly higher bone-implantcontact (BIC) and torque release forces than the titanium reference. The BIC of the stainless steel implants was significant lower than two of the anodized surfaces (p=0.04), but differences between stainless steel and all titanium implants in torque release forces were not significant (p=0.06). Conclusion: The new anodized titanium surfaces showed good bone-implant bonding despite a smooth surface and increased nanohardness. However, they failed to facilitate implant removal at 3 months.
Collapse
|
44
|
Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia 2017; 31:2347-2354. [PMID: 28322237 PMCID: PMC6037311 DOI: 10.1038/leu.2017.92] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 03/01/2017] [Accepted: 03/03/2017] [Indexed: 02/08/2023]
Abstract
Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Arsenic Trioxide
- Arsenicals/therapeutic use
- Female
- Humans
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/etiology
- Leukemia, Promyelocytic, Acute/genetics
- Male
- Middle Aged
- Neoplasms, Second Primary/drug therapy
- Neoplasms, Second Primary/etiology
- Neoplasms, Second Primary/genetics
- Oxides/therapeutic use
- Remission Induction
- Survival Analysis
- Treatment Outcome
- Young Adult
Collapse
Affiliation(s)
- S Kayser
- Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany
- Department of Internal Medicine V, Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), University of Heidelberg, Heidelberg, Germany
| | - J Krzykalla
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - MA Elliott
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - K Norsworthy
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| | - P Gonzales
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
| | - RK Hills
- Cardiff University School of Medicine, Cardiff, UK
| | - MR Baer
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Z Ráčil
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - J Novak
- 3rd Faculty of Medicine, Department of Internal Medicine and Haematology, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
| | - P Žák
- Faculty of Medicine, 4th Department of Internal Medicine-Hematology, Charles University and University Hospital Hradec Králové, Hradec Králové, Czech Republic
| | - T Szotkowski
- Faculty of Medicine and Dentistry, Department of Hemato-Oncology, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic
| | - D Grimwade
- Faculty of Life Sciences and Medicine, Department of Medical & Molecular Genetics, King’s College London, London, UK
| | - NH Russell
- Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - RB Walter
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - EH Estey
- Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Hematology/Department of Medicine, University of Washington, Seattle, WA, USA
| | - J Westermann
- Department of Hematology, Oncology and Tumor Immunology, Charité-University Medical Center, Campus Virchow Clinic, Berlin, Germany
| | - M Görner
- Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Bielefeld Mitte, Bielefeld, Germany
| | - A Benner
- Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
| | - A Krämer
- Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany
- Department of Internal Medicine V, Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), University of Heidelberg, Heidelberg, Germany
| | - BD Smith
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| | - AK Burnett
- Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - C Thiede
- Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
| | - C Röllig
- Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
| | - AD Ho
- Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany
| | - G Ehninger
- Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
| | - RF Schlenk
- National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - MS Tallman
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
| | - MJ Levis
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| | - U Platzbecker
- Department of Internal Medicine I, University Hospital Carl-Gustav-Carus, Dresden, Germany
| |
Collapse
|
45
|
Sarkar P, Gandhi A, Plosker S, Ying Y, Mayer J, Imudia A. The impact of supraphysiologic estradiol (E2) level during IVF on oocyte / embryo quality and pregnancy outcome. Fertil Steril 2017. [DOI: 10.1016/j.fertnstert.2017.07.1039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, Malcikova J, Oltova A, Kotaskova J, Tichy B, Brychtova Y, Mayer J, Doubek M, Pospisilova S. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. Leukemia 2017; 32:234-236. [PMID: 28937682 PMCID: PMC5770588 DOI: 10.1038/leu.2017.274] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- K Brazdilova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - K Plevova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - H Skuhrova Francova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - H Kockova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - M Borsky
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - V Bikos
- Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - J Malcikova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - A Oltova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - J Kotaskova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - B Tichy
- Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - Y Brychtova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - J Mayer
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - M Doubek
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - S Pospisilova
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.,Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| |
Collapse
|
47
|
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017; 31:2398-2406. [PMID: 28804124 PMCID: PMC5668495 DOI: 10.1038/leu.2017.253] [Citation(s) in RCA: 185] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 07/04/2017] [Indexed: 01/06/2023]
Abstract
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.
Collapse
Affiliation(s)
- R Hehlmann
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - M Lauseker
- IBE, Universität München, Munich, Germany
| | - S Saußele
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | | | - S Krause
- Medizinische Klinik 5, Universitätsklinikum, Erlangen, Germany
| | - H J Kolb
- Medizinische Klinik III, Universität München, Munich, Germany
| | - A Neubauer
- Klinik für innere Medizin, Universitätsklinikum, Marburg, Germany
| | - D K Hossfeld
- 2. Medizinische Klinik, Universitätsklinikum Eppendorf, Hamburg, Germany
| | - C Nerl
- Klinikum Schwabing, Munich, Germany
| | | | | | - D Heim
- Universitätsspital, Basel, Switzerland
| | | | - A Fabarius
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | | | | | - M C Müller
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | | | - U Proetel
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - K Kohlbrenner
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - A Voskanyan
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - S Rinaldetti
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - W Seifarth
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | - B Spieß
- III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
| | | | - M C Goebeler
- Medizinische Klinik und Poliklinik, Universitätsklinikum, Würzburg, Germany
| | - M Hänel
- Klinik für innere Medizin 3, Chemnitz, Germany
| | - A Ho
- Medizinische Klinik V, Universität Heidelberg, Heidelberg, Germany
| | - J Dengler
- Onkologische Schwerpunktpraxis, Heilbronn, Germany
| | - C Falge
- Medizinische Klinik 5, Klinikum Nürnberg-Nord, Nürnberg, Germany
| | - L Kanz
- Medizinische Abteilung 2, Universitätsklinikum, Tübingen, Germany
| | - S Kremers
- Caritas Krankenhaus, Lebach, Germany
| | - A Burchert
- Klinik für innere Medizin, Universitätsklinikum, Marburg, Germany
| | - M Kneba
- 2. Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - F Stegelmann
- Klinik für Innere Medizin 3, Universitätsklinikum, Ulm, Germany
| | - C A Köhne
- Klinik für Onkologie und Hämatologie, Oldenburg, Germany
| | | | - C F Waller
- Innere Medizin 1, Universitätsklinikum, Freiburg, Germany
| | - M Pfreundschuh
- Klinik für Innere Medizin 1, Universität des Saarlandes, Homburg, Germany
| | - K Spiekermann
- Medizinische Klinik III, Universität München, Munich, Germany
| | - W E Berdel
- Medizinische Klinik A, Universitätsklinikum, Münster, Germany
| | - L Müller
- Onkologie Leer UnterEms, Leer, Germany
| | - M Edinger
- Klinik und Poliklinik für Innere Medizin 3, Universitätsklinikum, Regensburg, Germany
| | - J Mayer
- Masaryk University Hospital, Brno, Czech Republic
| | - D W Beelen
- Klinik für Knochenmarktransplantation, Essen, Germany
| | - M Bentz
- Medizinische Klinik 3, Städtisches Klinikum, Karlsruhe, Germany
| | - H Link
- Klinik für Innere Medizin 3, Westpfalz-Klinikum, Kaiserslautern, Germany
| | - B Hertenstein
- 1. Medizinische Klinik, Klinikum Bremen Mitte, Bremen, Germany
| | | | - M Wernli
- Kantonsspital, Aarau, Switzerland
| | - F Schlegel
- St Antonius-Hospital, Eschweiler, Germany
| | - R Schlag
- Hämatologische-Onkologische Schwerpunktpraxis, Würzburg, Germany
| | - M de Wit
- Vivantes Klinikum Neukölln, Berlin, Germany
| | - L Trümper
- Klinik für Hämatologie und medizinische Onkologie, Universitätsmedizin, Göttingen, Germany
| | - H Hebart
- Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
| | - M Hahn
- Onkologie Zentrum, Ansbach, Germany
| | - J Thomalla
- Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany
| | - C Scheid
- Klinik 1 für Innere Medizin, Universitätsklinikum, Köln, Germany
| | - P Schafhausen
- 2. Medizinische Klinik, Universitätsklinikum Eppendorf, Hamburg, Germany
| | - W Verbeek
- Ambulante Hämatologie und Onkologie, Bonn, Germany
| | - M J Eckart
- Internistische Schwerpunktpraxis, Erlangen, Germany
| | | | | | - M Schenk
- Barmherzige Brüder, Regensburg, Germany
| | - P Brossart
- Medizinische Klinik 3, Universität, Bonn, Germany
| | - T Geer
- Diakonie, Schwäbisch Hall, Germany
| | - S Bildat
- Medizinische Klinik 2, Herford, Germany
| | - E Schäfer
- Onkologische Schwerpunktpraxis, Bielefeld, Germany
| | - A Hochhaus
- Klinik für Innere Medizin 2, Universitätsklinikum, Jena, Germany
| | - J Hasford
- IBE, Universität München, Munich, Germany
| |
Collapse
|
48
|
Dubový P, Klusáková I, Kučera L, Osičková J, Chovancová J, Loja T, Mayer J, Doubek M, Joukal M. Local chemical sympathectomy of rat bone marrow and its effect on marrow cell composition. Auton Neurosci 2017; 206:19-27. [PMID: 28688831 DOI: 10.1016/j.autneu.2017.06.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 06/22/2017] [Accepted: 06/22/2017] [Indexed: 01/08/2023]
Abstract
Existing experimental studies of the effect of sympathetic nerve fibers on bone marrow cells are based on the systemic administration of neurotoxic 6-hydroxydopamine. The method of global chemical sympathectomy has some serious disadvantages and could lead to questionable results. We describe a new method of local chemical sympathectomy of rat femoral bone marrow using guanethidine (Ismelin) delivery using an osmotic mini pump. Local guanethidine treatment for 14days led to complete elimination of sympathetic fibers in femoral bone marrow in contrast to bone marrow of contralateral or naïve femurs. Ablation of sympathetic fibers was associated with a loss of rat endothelial cell marker (RECA) indicating immunophenotype changes in blood vessel endothelial cells, but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro. Moreover, local guanethidine treatment also elicited a significant reduction of Nestin+/SDF1+ mesenchymal stem cells and c-Kit+/CD90+ hematopoietic stem cells in femoral bone marrow. Tissue-specific chemical sympathectomy of rat bone marrow by guanethidine overcomes some of the drawbacks of systemic administration of neurotoxic compounds like 6-hydroxydopamine and delivers unequivocal evidence on the effects of sympathetic innervation on the cell content of bone marrow.
Collapse
Affiliation(s)
- P Dubový
- Department of Anatomy, Faculty of Medicine, Masaryk University, Czech Republic.
| | - I Klusáková
- Department of Anatomy, Faculty of Medicine, Masaryk University, Czech Republic
| | - L Kučera
- Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Czech Republic
| | - J Osičková
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - J Chovancová
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - T Loja
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - J Mayer
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - M Doubek
- Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
| | - M Joukal
- Department of Anatomy, Faculty of Medicine, Masaryk University, Czech Republic
| |
Collapse
|
49
|
Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia 2017. [PMID: 28626220 PMCID: PMC5596208 DOI: 10.1038/leu.2017.192] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 weeks of subcutaneous darbepoetin alfa 500 μg or placebo every 3 weeks (Q3W), followed by 48 weeks of open-label darbepoetin alfa. A total of 147 patients were randomized, with median hemoglobin of 9.3 (Q1:8.8, Q3:9.7) g/dl and median baseline serum EPO of 69 (Q1:36, Q3:158) mU/ml. Transfusion incidence from weeks 5–24 was significantly lower with darbepoetin alfa versus placebo (36.1% (35/97) versus 59.2% (29/49), P=0.008) and erythroid response rates increased significantly with darbepoetin alfa (14.7% (11/75 evaluable) versus 0% (0/35 evaluable), P=0.016). In the 48-week open-label period, dose frequency increased from Q3W to Q2W in 81% (102/126) of patients; this was associated with a higher hematologic improvement–erythroid response rate (34.7% (34/98)). Safety results were consistent with a previous darbepoetin alfa phase 2 MDS trial. In conclusion, 24 weeks of darbepoetin alfa Q3W significantly reduced transfusions and increased rates of erythroid response with no new safety signals in lower-risk MDS (registered as EudraCT#2009-016522-14 and NCT#01362140).
Collapse
Affiliation(s)
- U Platzbecker
- University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
| | - A Symeonidis
- Division of Hematology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece
| | - E N Oliva
- Division of Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
| | - J S Goede
- Division of Hematology, University Hospital and University of Zürich, Zürich, Switzerland
| | - M Delforge
- Department of Hematology &Chairman Leuven Cancer Institute, University Hospital Leuven, Leuven, Belgium
| | - J Mayer
- Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - B Slama
- Oncologie Médicale-Hématologie Clinique, Centre Hospitalier Departemental, Avignon, France
| | - S Badre
- Amgen Inc., Thousand Oaks, CA, USA
| | - E Gasal
- Amgen Inc., Thousand Oaks, CA, USA
| | - B Mehta
- Amgen Inc., Thousand Oaks, CA, USA
| | | |
Collapse
|
50
|
Šustková Z, Čulen M, Semerád L, Ježíšková I, Dvořáková D, Ráčil Z, Mayer J. [New Drugs in the Treatment of Acute Myeloid Leukemia in the Elderly]. Klin Onkol 2017; 30:190-196. [PMID: 28612615 DOI: 10.14735/amko2017190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND At the time of diagnosis, most patients with acute myeloid leukemia are older than 65 years of age. Treatment of this group of patients is challenging because they become less tolerant to aggressive chemotherapy with increasing age. Less than one-third of elderly patients are considered eligible for intensive treatment; nevertheless, the survival analysis for this population remains poor. Due to numerous comorbidities and an overall deteriorating condition, most elderly patients with acute myeloid leukemia receive only palliative or best supportive care, which are associated with a high mortality rate. New therapeutic approaches are expected to improve the overall survival and quality of life of this group of patients. These promising treatments include cell kinase inhibitors, cytotoxic agents, monoclonal antibodies, and epigenetic therapy including hypomethylating agents and inhibitors of isocitrate dehydrogenase and histone deacetylase. In monotherapy, these new drugs show lower levels of toxicity than those commonly used in chemotherapy; however, they do not lead to a better long-lasting treatment response. To enhance therapeutic efficacy, combinations of the above-mentioned treatments are often used, and, during clinical trials, combinations with standard cytostatics are also common. The promising results of these studies show that even low-toxicity therapies can lead to a better overall treatment response and to longer overall survival. AIM This article provides a brief overview of new drugs that are evaluated for their mechanism of effect, efficacy and toxicity in therapy of patients suffering from acute myeloid leukemia.Key words: acute myeloid leukemia - elderly - FLT3 inhibitors - epigenetic therapy - monoclonal antibodies The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 4. 11. 2016Accepted: 13. 12. 2016.
Collapse
|